Literature DB >> 7595183

Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease.

S Nityanand1, C Bergmark, U de Faire, J Swedenborg, G Holm, A K Lefvert.   

Abstract

OBJECTIVES: To investigate the prevalence of anticardiolipin and antiendothelial cell antibodies in patients operated on for atherosclerotic peripheral vascular disease before 50 years of age. The hypothesis to be tested was whether antibodies associated with an immune/inflammatory damage to the vascular wall were associated also with early atherosclerosis.
DESIGN: A case-control study.
SETTING: Departments of surgery and an immunological research laboratory, and routine laboratories of two tertiary referral hospitals.
SUBJECTS: All patients operated for atherosclerotic peripheral vascular disease before 50 years of age. Sixty-two patients (33 males, 29 females), and 67 age- and sex-matched controls participated. The diagnosis of atherosclerosis was made on the basis of the clinical presentation and angiographic visualization of the diseased vasculature. MAIN OUTCOME MEASURES: Subjects were compared for the prevalence of anticardiolipin and antiendothelial cell antibodies, altered serum lipoprotein levels, smoking, diabetes, hypertension, and signs of inflammation.
RESULTS: Antibodies against endothelial cells and cardiolipin were found in 12.9 and 14.5% of the patients, respectively, which was higher than observed in the control group (P < 0.05). Sixty per cent of patients with antibodies were females. Conventional risk factors were more often noted in the patient group. However, patients with antibodies against endothelial cell and/or cardiolipin had a lower prevalence of hyperlipidaemia/dyslipidaemia when compared to patients without these antibodies (P < 0.05).
CONCLUSIONS: Antibodies against endothelial cells and cardiolipin are present in a subset of patients with clinical and angiographic diagnosis of severe premature atherosclerotic peripheral vascular disease. The lower occurrence of hyperlipidaemia/dyslipidaemia in patients with autoantibodies, in comparison to patients without the antibodies, suggests that these antibodies have a role in vascular damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595183     DOI: 10.1111/j.1365-2796.1995.tb01221.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Anti-cardiolipin antibodies and circulating immune complexes in type 1 diabetes mellitus: increased prevalence and relation to vascular complications.

Authors:  E Ahmed; S Nityanand; A Mustafa; K Brismar; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

2.  Should we be testing for antiphospholipid antibodies in unexplained pulmonary thromboembolism and atherosclerosis at autopsy?

Authors:  Christopher Bierton; Neil E I Langlois
Journal:  Forensic Sci Med Pathol       Date:  2013-03-13       Impact factor: 2.007

3.  Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice.

Authors:  X Zhou; G Paulsson; S Stemme; G K Hansson
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 4.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 5.  Vasa vitae--keeping the channels open.

Authors:  A A D'Sa
Journal:  Ulster Med J       Date:  1998-06

Review 6.  Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration.

Authors:  Heather M Wilkins; Ian W Weidling; Yan Ji; Russell H Swerdlow
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.